The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | The importance of proteomic analysis in myeloma and future outlooks
Arun Wiita, MD, PhD, University of California, San Francisco, CA, shares some insights into a session held at IMS 2022 which focused on the importance of proteomic analysis in multiple myeloma, and further discusses how proteomics can provide valuable information on mechanisms of myeloma progression and response to therapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
